Перейти к содержимому
Bending the Curve Trial by Trial
?EN

Назад: Рак яичников

Список литературы: Рак яичников

134 источника, процитированных на этой странице. Ссылки ведут к первоисточнику.

  1. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-4. PubMed
    ЦитироватьЗагрузка…
  2. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61(4):413-20. PubMed
    ЦитироватьЗагрузка…
  3. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47(2):159-66. PubMedDOI
    ЦитироватьЗагрузка…
  4. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974-9; discussion 979-80. PubMedDOI
    ЦитироватьЗагрузка…
  5. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71. PubMedDOI
    ЦитироватьЗагрузка…
  6. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-92. PubMedDOI
    ЦитироватьЗагрузка…
  7. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950-5. PubMedDOI
    ЦитироватьЗагрузка…
  8. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6. PubMedDOI
    ЦитироватьЗагрузка…
  9. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699-708. PubMedDOI
    ЦитироватьЗагрузка…
  10. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001-7. PubMedDOI
    ЦитироватьЗагрузка…
  11. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451-6. PubMedDOI
    ЦитироватьЗагрузка…
  12. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700-10. PubMedDOI
    ЦитироватьЗагрузка…
  13. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-59. PubMedDOI
    ЦитироватьЗагрузка…
  14. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360(9332):505-15. PubMedDOI
    ЦитироватьЗагрузка…
  15. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-15. PubMedDOI
    ЦитироватьЗагрузка…
  16. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320-9. PubMedDOI
    ЦитироватьЗагрузка…
  17. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-200. PubMedDOI
    ЦитироватьЗагрузка…
  18. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43. PubMedDOI
    ЦитироватьЗагрузка…
  19. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161-9. PubMedDOI
    ЦитироватьЗагрузка…
  20. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-44. PubMedDOI
    ЦитироватьЗагрузка…
  21. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-8. PubMedDOI
    ЦитироватьЗагрузка…
  22. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-75. PubMedDOI
    ЦитироватьЗагрузка…
  23. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-43. PubMedDOI
    ЦитироватьЗагрузка…
  24. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53. PubMedDOI
    ЦитироватьЗагрузка…
  25. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-83. PubMedDOI
    ЦитироватьЗагрузка…
  26. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-303. PubMedDOI
    ЦитироватьЗагрузка…
  27. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-96. PubMedDOI
    ЦитироватьЗагрузка…
  28. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-7. PubMedDOI
    ЦитироватьЗагрузка…
  29. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-45. PubMedDOI
    ЦитироватьЗагрузка…
  30. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-63. PubMedDOI
    ЦитироватьЗагрузка…
  31. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-92. PubMedDOI
    ЦитироватьЗагрузка…
  32. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020-6. PubMedDOI
    ЦитироватьЗагрузка…
  33. FDA. Supplement approval letter, BLA 125085/S-305 (replacement letter) (Avastin, bevacizumab), signed 14 November 2014. Источник
  34. FDA. Approval letter (headed accelerated approval), NDA 206162 (Lynparza, olaparib capsules), signed 19 December 2014. Источник
  35. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75. PubMedDOI
    ЦитироватьЗагрузка…
  36. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-8. PubMedDOI
    ЦитироватьЗагрузка…
  37. Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015;107(2). PubMedDOI
    ЦитироватьЗагрузка…
  38. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244-50. PubMedDOI
    ЦитироватьЗагрузка…
  39. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57. PubMedDOI
    ЦитироватьЗагрузка…
  40. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928-36. PubMedDOI
    ЦитироватьЗагрузка…
  41. Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016;374(8):738-48. PubMedDOI
    ЦитироватьЗагрузка…
  42. FDA. Supplement approval letter, BLA 125085/S-317 (Avastin, bevacizumab), signed 6 December 2016. Источник
  43. FDA. Approval letter (headed accelerated approval), NDA 209115 (Rubraca, rucaparib), signed 19 December 2016. Источник
  44. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945-956. PubMedDOI
    ЦитироватьЗагрузка…
  45. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579-1589. PubMedDOI
    ЦитироватьЗагрузка…
  46. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164. PubMedDOI
    ЦитироватьЗагрузка…
  47. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016;2(4):482-90. PubMedDOI
    ЦитироватьЗагрузка…
  48. Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016;143(2):270-275. PubMedDOI
    ЦитироватьЗагрузка…
  49. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949-1961. PubMedDOI
    ЦитироватьЗагрузка…
  50. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779-791. PubMedDOI
    ЦитироватьЗагрузка…
  51. FDA. Supplement approval letter (with a Subpart H fulfilled section), NDA 206162/S-007 (Lynparza, olaparib capsules), signed 17 August 2017. Источник
  52. FDA. Approval letter, NDA 208558 (Lynparza, olaparib tablets), signed 17 August 2017. Источник
  53. FDA. Approval letter, NDA 208447 (Zejula, niraparib capsules), signed 27 March 2017. Источник
  54. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. PubMedDOI
    ЦитироватьЗагрузка…
  55. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274-1284. PubMedDOI
    ЦитироватьЗагрузка…
  56. FDA. Supplement approval letter, BLA 125085/S-323 (Avastin, bevacizumab), signed 13 June 2018. Источник
  57. FDA. Supplement approval letter, NDA 208558/S-006 (Lynparza, olaparib tablets), signed 19 December 2018. Источник
  58. FDA. Supplement approval letter (Subpart H fulfilled), NDA 209115/S-003 (Rubraca, rucaparib), signed 6 April 2018. Источник
  59. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505. PubMedDOI
    ЦитироватьЗагрузка…
  60. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, et al. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(6):588-594. PubMedDOI
    ЦитироватьЗагрузка…
  61. US Preventive Services Task Force. Ovarian Cancer: Screening. Final Recommendation Statement, 13 February 2018 (recommendation summary and clinician summary, grade D). Page accessed 21 October 2026. Источник
  62. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(3):230-240. PubMedDOI
    ЦитироватьЗагрузка…
  63. Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394(10214):2084-2095. PubMedDOI
    ЦитироватьЗагрузка…
  64. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019;381(20):1929-1939. PubMedDOI
    ЦитироватьЗагрузка…
  65. FDA. Supplement approval letter, NDA 208447/S-014 (Zejula, niraparib tablets), signed 23 October 2019. Источник
  66. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391-2402. PubMedDOI
    ЦитироватьЗагрузка…
  67. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med. 2019;380(9):822-832. PubMedDOI
    ЦитироватьЗагрузка…
  68. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636-648. PubMedDOI
    ЦитироватьЗагрузка…
  69. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416-2428. PubMedDOI
    ЦитироватьЗагрузка…
  70. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019;37(26):2317-2328. PubMedDOI
    ЦитироватьЗагрузка…
  71. Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019;37(16):1380-1390. PubMedDOI
    ЦитироватьЗагрузка…
  72. Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657-1664. PubMedDOI
    ЦитироватьЗагрузка…
  73. FDA. Supplement approval letter, NDA 208558/S-013 (Lynparza, olaparib tablets), signed 8 May 2020. Источник
  74. FDA. Supplement approval letter, NDA 208447/S-015 and S-017 (Zejula, niraparib capsules), signed 29 April 2020. Источник
  75. Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(11):1222-1245. PubMedDOI
    ЦитироватьЗагрузка…
  76. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, et al. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020;38(32):3753-3762. PubMedDOI
    ЦитироватьЗагрузка…
  77. Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020;38(11):1164-1174. PubMedDOI
    ЦитироватьЗагрузка…
  78. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721-1731. PubMedDOI
    ЦитироватьЗагрузка…
  79. Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021;385(23):2123-2131. PubMedDOI
    ЦитироватьЗагрузка…
  80. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182-2193. PubMedDOI
    ЦитироватьЗагрузка…
  81. Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(9):1275-1289. PubMedDOI
    ЦитироватьЗагрузка…
  82. Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842-1855. PubMedDOI
    ЦитироватьЗагрузка…
  83. Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620-631. PubMedDOI
    ЦитироватьЗагрузка…
  84. Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439-449. PubMedDOI
    ЦитироватьЗагрузка…
  85. FDA. Approval letter (BLA accelerated approval), BLA 761310 (Elahere, mirvetuximab soravtansine-gynx), signed 14 November 2022. Источник
  86. FDA. Supplement approval letter, NDA 208558/S-026 (Lynparza, olaparib tablets), signed 26 August 2022. Источник
  87. FDA. Supplement approval letter, NDA 209115/S-011 (Rubraca, rucaparib), signed 10 June 2022. Источник
  88. FDA. Supplement approval letter, NDA 209115/S-013 (Rubraca, rucaparib), signed 21 December 2022. Источник
  89. FDA. Supplement approval letter, NDA 208447/S-025 (Zejula, niraparib), signed 8 December 2022. Источник
  90. FDA. Supplement approval letter, NDA 208447/S-026 (Zejula, niraparib), signed 14 September 2022. Источник
  91. Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553. PubMedDOI
    ЦитироватьЗагрузка…
  92. Hanley GE, Pearce CL, Talhouk A, Kwon JS, Finlayson SJ, McAlpine JN, et al. Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Netw Open. 2022;5(2):e2147343. PubMedDOI
    ЦитироватьЗагрузка…
  93. Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(4):465-478. PubMedDOI
    ЦитироватьЗагрузка…
  94. Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, et al. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg. 2022;157(5):374-383. PubMedDOI
    ЦитироватьЗагрузка…
  95. Tew WP, Lacchetti C, Kohn EC. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022;40(33):3878-3881. PubMedDOI
  96. DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023;41(3):609-617. PubMedDOI
    ЦитироватьЗагрузка…
  97. FDA. Supplement approval letter, NDA 208558/S-029 (Lynparza, olaparib tablets), signed 12 September 2023; revises the recurrent ovarian cancer maintenance indication to BRCA-mutated disease and refers to the FDA letter of 15 June 2023 under section 505(o)(4). Источник
  98. González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908. PubMedDOI
    ЦитироватьЗагрузка…
  99. Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023;41(13):2436-2445. PubMedDOI
    ЦитироватьЗагрузка…
  100. Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389(23):2162-2174. PubMedDOI
    ЦитироватьЗагрузка…
  101. Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681-692. PubMedDOI
    ЦитироватьЗагрузка…
  102. Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024;25(12):1551-1562. PubMedDOI
    ЦитироватьЗагрузка…
  103. FDA. Supplement approval letter (Subpart E fulfilled), BLA 761310/S-005 (Elahere), signed 22 March 2024. Источник
  104. FDA. Clovis Oncology, Inc., AstraZeneca Pharmaceuticals LP, and GlaxoSmithKline LLC; Withdrawal of Approval of the Indications for Advanced Ovarian Cancer for Poly (ADP-Ribose) Polymerase Inhibitors RUBRACA (Rucaparib) Tablets, LYNPARZA (Olaparib) Tablets, and ZEJULA (Niraparib) Capsules. Federal Register notice, docket FDA-2024-N-1056, 26 March 2024; 89 FR 20982. Источник
  105. Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024;35(11):981-992. PubMedDOI
    ЦитироватьЗагрузка…
  106. Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, et al. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025;43(25):2782-2792. PubMedDOI
    ЦитироватьЗагрузка…
  107. FDA. Approval letter (accelerated approval), NDA 219616 (Avmapki Fakzynja co-pack: avutometinib and defactinib), signed 8 May 2025. Источник
  108. FDA. Supplement approval letter, NDA 214876/S-003 and S-004 (Zejula, niraparib tablets), signed 18 June 2025; narrows the first-line maintenance indication to HRD-positive tumours. Источник
  109. Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. J Clin Oncol. 2025;43(7):868-891. PubMedDOI
    ЦитироватьЗагрузка…
  110. Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025;405(10496):2205-2216. PubMedDOI
    ЦитироватьЗагрузка…
  111. FDA. AVASTIN (bevacizumab) prescribing information, Indications and Usage section 1 (label version 39, effective 6 January 2025; text read through the openFDA drug label API and also available on DailyMed, set id 939b5d1f-9fb2-4499-80ef-0607aa6b114e). Record accessed 21 October 2026. Источник
  112. FDA. LYNPARZA (olaparib) tablets prescribing information, Indications and Usage section 1 (label version 38, effective 10 July 2025; text read through the openFDA drug label API and also available on DailyMed, set id 741ff3e3-dc1a-45a6-84e5-2481b27131aa). Record accessed 21 October 2026. Источник
  113. Oza AM, Lisyanskaya A, Fedenko A, de Melo AC, Shparyk Y, Rakhmatullina I, et al. Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2025;26(2):249-264. PubMedDOI
    ЦитироватьЗагрузка…
  114. American College of Obstetricians & Gynecologists Committee on Clinical Consensus—Gynecology. ACOG Clinical Practice Update: Salpingectomy for the Prevention of Epithelial Ovarian Cancer. Obstet Gynecol. 2026;148(4):e275-e280. PubMedDOI
  115. Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, et al. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2026;407(10538):1525-1537. PubMedDOI
    ЦитироватьЗагрузка…
  116. ClinicalTrials.gov. NCT03772028 (OVHIPEC-2). Registry record, API v2, accessed 21 October 2026. NCT03772028
  117. ClinicalTrials.gov. NCT05445778 (GLORIOSA). Registry record, API v2, accessed 21 October 2026. NCT05445778
  118. ClinicalTrials.gov. NCT06072781 (RAMP 301). Registry record, API v2, accessed 21 October 2026. NCT06072781
  119. ClinicalTrials.gov. NCT06580314 (NRG-GY036). Registry record, API v2, accessed 21 October 2026. NCT06580314
  120. ClinicalTrials.gov. NCT06619236 (RAINFOL-02). Registry record, API v2, accessed 21 October 2026. NCT06619236
  121. ClinicalTrials.gov. NCT06819007 (DESTINY-Ovarian01). Registry record, API v2, accessed 21 October 2026. NCT06819007
  122. EMA. Elahere (mirvetuximab soravtansine): European public assessment report page, accessed 21 October 2026. Источник
  123. EMA. Lynparza (olaparib): European public assessment report page, accessed 19 October 2026. Источник
  124. EMA. Zejula (niraparib): European public assessment report page, accessed 21 October 2026. Источник
  125. FDA. Supplement approval letter, BLA 125514/S-186 (Keytruda, pembrolizumab), signed 10 February 2026. Источник
  126. FDA. Approval letter, NDA 220641 (Lifyorli, relacorilant), signed 25 March 2026. Источник
  127. FDA. Prescribing information, Mekinist (trametinib), NDA 204114/S-042, 2026 label (indications reviewed 21 October 2026). Источник
  128. US Food and Drug Administration. Verified Clinical Benefit | Cancer Accelerated Approvals. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Content current as of 16 October 2026. Источник
  129. FDA. Withdrawn: Cancer Accelerated Approvals (page lists 36 rows; content current as of 10/05/2026), accessed 21 October 2026. Источник
  130. González-Martín A, Ledermann JA. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer. ESMO Open. 2026;11(2):106032. PubMedDOI
  131. Lesnock JL, Temin S, Bouberhan S, Adams SF, Barber EL, Burkett WC, et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. 2026;44(28):2725-2744. PubMedDOI
  132. Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. Lancet. 2026;407(10538):1513-1524. PubMedDOI
    ЦитироватьЗагрузка…
  133. FDA. ZEJULA (niraparib) tablets prescribing information, Indications and Usage section 1 (label version 10, effective 28 July 2026; NDA 214876; text read through the openFDA drug label API and also available on DailyMed, set id b7f675e2-159c-490c-b6f4-3f16d9492b7d). Record accessed 21 October 2026. Источник
  134. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Ovarian Cancer. Page accessed 21 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Источник